Table 2 Pharmacokinetic parameters for hydromorphone after administration of OROS® hydromorphone to fasted and fed volunteers
| Parameter | Treatment Regimen A (fasting; n= 25) | Treatment Regimen B (fed; n= 27) | Treatment Regimen C (fasting with naltrexone block; n= 26) |
|---|---|---|---|
| Cmax (ng/mL) | |||
| Mean | 1.107 | 1.352 | 1.635 |
| SD | 0.2058 | 0.3633 | 0.5708 |
| Tmax (h) | |||
| Median | 16.0 | 12.0 | 12.0 |
| Range | 6.0–36.0 | 6.0–20.0 | 6.0–24.0 |
| t1/2 (h) | |||
| Mean | 14.7 | 12.5 | 10.1 |
| SD | 6.07 | 5.22 | 3.95 |
| AUC0-t (ng· h/mL) | |||
| Mean | 31.12 | 30.20 | 33.97 |
| SD | 7.063 | 8.738 | 9.007 |
| AUC0-∞(ng·h/mL) | |||
| Mean | 38.84 | 36.09 | 37.24 |
| SD | 9.566 | 10.04 | 9.921 |